Literature DB >> 7997005

Why monitor peak vancomycin concentrations?

N J Saunders1.   

Abstract

Peak and trough serum concentrations are routinely measured to monitor vancomycin therapy. Optimal therapy depends upon maintaining a concentration above that necessary for antibacterial activity and is therefore determined by the trough concentration. I determined the post dose increases in serum drug concentrations in routine clinical practice in adult patients without renal failure. Mean increases of 16.6 mg/L (SD 6.1) (peak samples collected 1 h post infusion) were measured from 165 paired samples. The results suggest that as long as trough concentrations do not exceed 15 mg/L, peak levels will not exceed normally accepted safe concentrations, and therefore do not need to be measured.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7997005     DOI: 10.1016/s0140-6736(94)92890-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  16 in total

1.  Recommendations for monitoring serum vancomycin concentrations.

Authors:  C W James; C Gurk-Turner
Journal:  Proc (Bayl Univ Med Cent)       Date:  2001-04

2.  Strategies for controlling antibiotic use in a tertiary-care paediatric hospital.

Authors:  S A Diamond; B J Hales
Journal:  Paediatr Child Health       Date:  1997-05       Impact factor: 2.253

3.  Vancomycin monitoring in children using bayesian estimation.

Authors:  Jennifer Le; Becky Ngu; John S Bradley; William Murray; Austin Nguyen; Lyn Nguyen; Gale L Romanowski; Tiana Vo; Edmund V Capparelli
Journal:  Ther Drug Monit       Date:  2014-08       Impact factor: 3.681

4.  Influence of age on frequency of vancomycin dosing.

Authors:  Michael Legal; Marisa Wan
Journal:  Can J Hosp Pharm       Date:  2010-01

5.  Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit.

Authors:  J Albanèse; M Léone; B Bruguerolle; M L Ayem; B Lacarelle; C Martin
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

6.  Questioning the accuracy of trough concentrations as surrogates for area under the curve in determining vancomycin safety.

Authors:  Cameron J Phillips
Journal:  Ther Adv Drug Saf       Date:  2014-06

7.  Correlation of vancomycin dosing to serum concentrations in pediatric patients: a retrospective database review.

Authors:  Kim W Benner; Mary A Worthington; David W Kimberlin; Kim Hill; Kevin Buckley; Nancy M Tofil
Journal:  J Pediatr Pharmacol Ther       Date:  2009-04

Review 8.  Teicoplanin. A pharmacoeconomic evaluation of its use in the treatment of gram-positive infections.

Authors:  C M Spencer; H M Bryson
Journal:  Pharmacoeconomics       Date:  1995-04       Impact factor: 4.981

Review 9.  Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis.

Authors:  Jason A Roberts; Jeffrey Lipman
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 10.  Vancomycin: pharmacokinetics and administration regimens in neonates.

Authors:  Matthijs de Hoog; Johan W Mouton; John N van den Anker
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.